MedPath

Metformin

Generic Name
Metformin
Brand Names
Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
Drug Type
Small Molecule
Chemical Formula
C4H11N5
CAS Number
657-24-9
Unique Ingredient Identifier
9100L32L2N
Background

Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.

Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.

Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.

Indication

Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)

The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.

Metformin combination products

Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.

Associated Conditions
Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
Associated Therapies
-
Clinical Trials
Related News
nature.com
·

Patient-centred clinical trial design

The article highlights the importance of patient involvement in clinical trials and research, especially in nephrology. It discusses various studies and initiatives aimed at improving patient engagement, setting research priorities, and developing patient-centered outcomes. Key themes include the need for transparent communication, the development of core outcome sets, and strategies to enhance recruitment and retention in trials.

Related Clinical Trials:

Wearable Cardioverter Defibrillator in Hemodialysis Patients (WED-HED) Study
frontiersin.org
·

Antibody-Drug Conjugates Targeting the Human HER Family for Cancer Therapy

The HER family, including EGFR, HER2, HER3, and HER4, plays crucial roles in cell regulation and is implicated in various cancers. Overexpression of HER receptors, particularly EGFR and HER2, is common in tumors. Antibody-drug conjugates (ADCs) combine antibodies' specificity with cytotoxic drugs' potency, targeting HER receptors for cancer therapy. Three anti-HER2 ADCs are approved, with over 100 in trials. Challenges include improving ADC uptake, reducing toxicity, and overcoming resistance. Future directions focus on antibody engineering, ADC design improvements, and combination therapies to enhance efficacy and reduce side effects.

Related Clinical Trials:

Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
A Study of MRG003 in Patients With Advanced Solid Tumors
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
M1231 in Participants With Solid Tumors
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2
A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression
SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
ARX788 in Breast Cancer With Low Expression of HER2
ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors
Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
pmc.ncbi.nlm.nih.gov
·

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: A review of efficacy and quality of life impacts

Studies on PARPi in ovarian cancer show improved progression-free survival (PFS) but unclear overall survival (OS) benefits. Quality of life (QoL) data is heterogeneous, with some studies indicating maintained QoL during treatment. Serious adverse events are more common with PARPi, impacting QoL. Evidence is most robust for olaparib, with less data for other PARPis. Long-term follow-up is needed for clearer OS outcomes.
express.co.uk
·

Diabetes 'wonder-drug' stuns scientist as it's linked with anti-ageing: 'Very interesting'

Dr David Lloyd highlights metformin, a diabetes drug, for its potential anti-aging effects. Research suggests it may extend life beyond diabetes treatment, with studies indicating benefits against cancer, heart disease, and dementia. However, Dr Lloyd cautions against its widespread use without further research.
pmc.ncbi.nlm.nih.gov
·

Patient Preferences for Release of Test Results of Increasing Severity

A survey of 8030 respondents revealed preferences for receiving medical test results: 74% favored electronic portals for cholesterol tests, while 54% preferred in-person appointments for cancer results. Acceptance of portal results varied by test severity, income, and education, with higher acceptance for less serious tests and among lower-income, less-educated respondents. Emotional impact and need for provider explanation were key concerns for serious results.
onlinescientificresearch.com
·

Fulltext | Current State of Regulatory Oversight of Biosimilars

Biosimilars in India face quality concerns due to fewer clinical studies compared to approvals. The article compares US, EU, and Indian biosimilar regulations, highlighting India's need for stricter guidelines and post-approval monitoring to ensure drug quality and international compliance.
pmc.ncbi.nlm.nih.gov
·

How Much Does It Cost to Research and Develop a New Drug

The article reviews R&D cost estimates for bringing new drugs to market, ranging from $161M to $4.5B. Factors like therapeutic class, drug sample period, and methodology affect costs. Recent studies suggest higher costs, but exceptions exist. The review highlights the complexity and variability in R&D cost estimations, emphasizing the need for comprehensive analysis.
pmc.ncbi.nlm.nih.gov
·

Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- early breast cancer

Adjuvant CDK4/6 inhibitors with ET showed potential in prolonging IDFS for HR+/HER2- EBC, especially in N2/N3 patients, but with higher grade 3/4 AEs and treatment discontinuation risks. Evidence remains inconclusive, necessitating further trials for validation.

Related Clinical Trials:

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
PALbociclib CoLlaborative Adjuvant Study
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
pmc.ncbi.nlm.nih.gov
·

TERT Promoter Alterations in Glioblastoma: A Systematic Review

Glioblastoma, a highly aggressive brain tumor, frequently exhibits TERT promoter mutations, crucial for telomere maintenance and cancer cell survival. This review highlights the role of TERT alterations in glioblastoma's pathophysiology, diagnosis, and potential therapeutic targets, emphasizing the need for innovative treatments to improve patient outcomes.

Related Clinical Trials:

Universal Cancer Peptide-based Vaccination in Metastatic NSCLC
Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer
Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma
pmc.ncbi.nlm.nih.gov
·

Effectiveness and safety of sodium‐glucose co‐transporter inhibitors in older adults with type 2 diabetes

SGLT2 inhibitors in older adults with type 2 diabetes significantly lower risks of heart failure, all-cause death, and stroke compared to DPP-4 inhibitors, despite higher risks of genital and urinary tract infections. Benefits may diminish in those aged ≥75 years. More research is needed for very elderly patients.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy